Rubicon Research Facebook Rubicon Research Linkedin

Rubicon Research Commits Rs 2 Crore for the Fight Against COVID-19

Thane, Mumbai (India), April 30, 2020

Rubicon Research Pvt Ltd has committed Rs 2 crore to support India’s fight against the coronavirus pandemic. The support will be by way of the following initiatives:

  • Donating Rs 1.9 crore worth of Hydroxychloroquine (1.5 million tablets) and various immunity boosting products, like Vitamin C and Vitamin C + Zinc controlled release tablets, to the Government of Maharashtra to help frontline workers and high-risk patients
  • Contribution of Rs 5 lakh towards the PM CARES Fund
  • Contribution of Rs 5 lakh towards the Maharashtra Chief Minister’s Relief Fund
  • Providing protective gear and sanitizers to state public servants and healthcare workers
  • Supporting NGOs distributing food among migrant laborers

Hydroxychloroquine donation

To meet the urgent demand for Hydroxychloroquine, the company took on the challenge of producing the medicine on April 5 using its formulation previously developed for other global markets, and 20 days later the first two batches were ready for dispatch. The company is now further scaling up capacity to increase production in line with its commitment of 1.5 million tablets.

The fight against COVID-19 will be a long-drawn out battle, with vaccines taking some time to arrive. Till a vaccine is available, people need to build a strong immune system to fight off COVID-19. Therefore, the company also plans to donate immunity boosters like Vitamin C controlled release tablets and Vitamin C + Zinc controlled release tablets to build resilience.

“All of us at Rubicon Research are proud to support the government during this unprecedented crisis,” said Parag Sancheti, CEO, Rubicon Research Pvt Ltd. “Our goal is to support frontline workers risking their lives while undertaking critical work against COVID-19. We are also carrying out our daily business with special precautions so as to ensure a continued supply of important medicines to patients, while safeguarding the health and safety of all our employees.”

Donations to government programs

As a concerned corporate citizen, the company has responded to the call of Prime Minister Narendra Modi and will also be donating Rs 5,00,000 to the PM CARES Fund and Rs 5,00,000 to Maharashtra Chief Minister’s Relief Fund to help support and provide relief to vulnerable groups and those communities that have been severely impacted by the pandemic.

Social and employee welfare activities

The company is committed to stepping up its social outreach and welfare initiatives. Protective gear and sanitizers have been donated to state public servants and healthcare workers. Rubicon Research is also contributing to local NGOs providing food relief to migrant laborers and the homeless. It is supporting its contract workers with fortnightly packages of essential grocery items. Additionally, a Hardship Bonus is being given to all employees who are present at work in different locations, providing the support needed to keep essential services running in these difficult times.

About Rubicon Research Pvt Ltd

Rubicon Research is an IP led, specialty pharmaceutical company focused on our mission to provide innovative yet affordable patient-centered products and solutions so as to address unmet needs around the world. We leverage our proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges; enabling better patient outcomes.
Our portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, topical, drug device combinations and fixed-dose combinations. We hold more than 50 issued patents in drug delivery technologies, and have launched over 40 SKUs, with over 1 billion extended units sold globally in 2019. Rubicon Research operates out of four locations—the corporate HQ and R&D center in Thane, India, the R&D center in Concord, Canada, the manufacturing site in Ambernath, India, and the business development and regulatory office in Plainsboro, US.

All media enquiries
Kermin Bhot
Senior Manager, Corporate Communications